Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2015 2
2016 2
2018 1
2019 1
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K, Varas L, Deronic A, Nyesiga B, Sundstedt A, Ljung L, Sakellariou C, Werchau D, Thagesson M, Gomez Jimenez D, Greiff L, Celander M, Smedenfors K, Rosén A, Bölükbas D, Carlsson F, Levin M, Säll A, von Schantz L, Lindstedt M, Ellmark P. Hägerbrand K, et al. Among authors: deronic a. J Immunother Cancer. 2022 Nov;10(11):e005018. doi: 10.1136/jitc-2022-005018. J Immunother Cancer. 2022. PMID: 36323431 Free PMC article.
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson MH, Fritzell S, Miller R, Werchau D, Van Citters D, Nilsson A, Misher L, Ljung L, Bader R, Deronic A, Chunyk AG, Schultz L, Varas LA, Rose N, Håkansson M, Gross J, Furebring C, Pavlik P, Sundstedt A, Veitonmäki N, Ramos HJ, Säll A, Dahlman A, Bienvenue D, von Schantz L, McMahan CJ, Askmyr M, Hernandez-Hoyos G, Ellmark P. Nelson MH, et al. Among authors: deronic a. Mol Cancer Ther. 2023 Jan 3;22(1):89-101. doi: 10.1158/1535-7163.MCT-22-0395. Mol Cancer Ther. 2023. PMID: 36343381 Free PMC article.
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A, Nilsson A, Thagesson M, Werchau D, Enell Smith K, Ellmark P. Deronic A, et al. Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642. doi: 10.1007/s00262-021-02932-5. Epub 2021 May 5. Cancer Immunol Immunother. 2021. PMID: 33948686 Free PMC article.
Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy.
Rydberg Millrud C, Deronic A, Grönberg C, Jaensson Gyllenbäck E, von Wachenfeldt K, Forsberg G, Liberg D. Rydberg Millrud C, et al. Among authors: deronic a. Cancer Immunol Immunother. 2023 Mar;72(3):667-678. doi: 10.1007/s00262-022-03277-3. Epub 2022 Aug 29. Cancer Immunol Immunother. 2023. PMID: 36036818 Free PMC article.
13 results